Validation of Embolic and Bleeding Risk Scores in Patients With Atrial Fibrillation and Cancer

      Little is known about the prediction of atrial fibrillation (AF) risk scores in patients with cancer. The aim of this study was to assess the predictive ability of the CHA2DS2-VASc and HAS-BLED scores in patients with AF and cancer. Overall, 16,056 patients with AF diagnosed between 2014 and 2018 from a Spanish health area, including 1,137 patients with cancer, were observed during a median follow-up of 4.9 years. Although discrimination was similar between patients with cancer and patients without cancer who were treated with anticoagulation therapy (0.56 and 0.58), in patients with cancer who were not treated with anticoagulation therapy, c-statistic of CHA2DS2-VASc was poor and significantly lower than in the patients without cancer (0.42 vs 0.65). The overall precision of the CHA2DS2-VASc score was good throughout the follow-up (Brier score < 0.1), in patients with and without cancer. Regarding the HAS-BLED score, calibration and discrimination were poor in patients with cancer (c-statistic 0.51), similar to those in patients without cancer (c-statistic 0.53). In patients with cancer who were not treated with anticoagulation therapy, the embolic risk CHA2DS2-VASc score = 1 was similar to CHA2DS2-VASc score ≥ 2. Only patients with AF and cancer and CHA2DS2-VASc score = 0 presented a low risk of embolic events (negative predictive value 100%). A HAS-BLED score > 3 was not associated with higher bleeding risk in patients with cancer (p > 0.05). In summary, in patients with cancer and with AF, neither the CHA2DS2-VASc score nor the HAS-BLED score was useful for predicting embolic and hemorrhagic events, respectively. However, a CHA2DS2-VASc score 0 is useful to identify patients with AF and cancer who are at low embolic risk.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • O'Neal WT
        • Lakoski SG
        • Qureshi W
        • Judd SE
        • Howard G
        • Howard VJ
        • Cushman M
        • Soliman EZ.
        Relation between cancer and atrial fibrillation (from the REasons for Geographic And Racial Differences in Stroke Study).
        Am J Cardiol. 2015; 115: 1090-1094
        • O'Neal WT
        • Claxton JS
        • Sandesara PB
        • MacLehose RF
        • Chen LY
        • Bengtson LGS
        • Chamberlain AM
        • Norby FL
        • Lutsey PL
        • Alonso A.
        Provider specialty, anticoagulation, and stroke risk in patients with atrial fibrillation and cancer.
        J Am Coll Cardiol. 2018; 72: 1913-1922
        • Mosarla RC
        • Vaduganathan M
        • Qamar A
        • Moslehi J
        • Piazza G
        • Giugliano RP.
        Anticoagulation strategies in patients with cancer: JACC review topic of the week.
        J Am Coll Cardiol. 2019; 73: 1336-1349
        • Sanz AP
        • Gómez JLZ.
        AF in cancer patients: a different need for anticoagulation?.
        Eur Cardiol. 2019; 14: 65-67
        • Zamorano JL
        • Lancellotti P
        • Rodriguez Muñoz D
        • Aboyans V
        • Asteggiano R
        • Galderisi M
        • Habib G
        • Lenihan DJ
        • Lip GYH
        • Lyon AR
        • Lopez Fernandez T
        • Mohty D
        • Piepoli MF
        • Tamargo J
        • Torbicki A
        • Suter TM
        • ESC Scientific Document Group
        2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC).
        Eur Heart J. 2016; 37: 2768-2801
        • Sorigue M
        • Miljkovic MD.
        Atrial fibrillation and stroke risk in patients with cancer: a primer for oncologists.
        J Oncol Pract. 2019; 15: 641-650
        • Khorana AA
        • Noble S
        • Lee AYY
        • Soff G
        • Meyer G
        • O'Connell C
        • Carrier M.
        Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH.
        J Thromb Haemost. 2018; 16: 1891-1894
        • Edge SB
        • Compton CC.
        The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM.
        Ann Surg Oncol. 2010; 17: 1471-1474
        • Chamie K
        • Williams SB
        • Hershman DL
        • Wright JD
        • Nguyen PL
        • Hu JC.
        Population-based assessment of determining predictors for quality of prostate cancer surveillance.
        Cancer. 2015; 121: 4150-4157
        • Armitage JO.
        Staging non-Hodgkin lymphoma.
        CA Cancer J Clin. 2005; 55: 368-376
        • Lip GY
        • Nieuwlaat R
        • Pisters R
        • Lane DA
        • Crijns HJ.
        Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation.
        Chest. 2010; 137: 263-272
        • Pisters R
        • Lane DA
        • Nieuwlaat R
        • de Vos CB
        • Crijns HJ
        • Lip GY.
        A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey.
        Chest. 2010; 138: 1093-1100
        • Hicks KA
        • Mahaffey KW
        • Mehran R
        • Nissen SE
        • Wiviott SD
        • Dunn B
        • Solomon SD
        • Marler JR
        • Teerlink JR
        • Farb A
        • Morrow DA
        • Targum SL
        • Sila CA
        • Thanh Hai MT
        • Jaff MR
        • Joffe HV
        • Cutlip DE
        • Desai AS
        • Lewis EF
        • Gibson CM
        • Landray MJ
        • Lincoff AM
        • White CJ
        • Brooks SS
        • Rosenfield K
        • Domanski MJ
        • Lansky AJ
        • McMurray JJV
        • Tcheng JE
        • Steinhubl SR
        • Burton P
        • Mauri L
        • O'Connor CM
        • Pfeffer MA
        • Hung HMJ
        • Stockbridge NL
        • Chaitman BR
        • Temple RJ
        Standardized Data Collection for Cardiovascular Trials Initiative (SCTI). 2017 cardiovascular and stroke endpoint definitions for clinical trials.
        J Am Coll Cardiol. 2018; 71: 1021-1034
        • Schulman S
        • Angerås U
        • Bergqvist D
        • Eriksson B
        • Lassen MR
        • Fisher W
        Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients.
        J Thromb Haemost. 2010; 8: 202-204
        • Kaatz S
        • Ahmad D
        • Spyropoulos AC
        • Schulman S
        Subcommittee on Control of Anticoagulation. Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH.
        J Thromb Haemost. 2015; 13: 2119-2126
        • Pastori D
        • Marang A
        • Bisson A
        • Menichelli D
        • Herbert J
        • Lip GYH
        • Fauchier L.
        Thromboembolism, mortality, and bleeding in 2,435,541 atrial fibrillation patients with and without cancer: a nationwide cohort study.
        Cancer. 2021; 127: 2122-2129
        • Boriani G
        • Lee G
        • Parrini I
        • Lopez-Fernandez T
        • Lyon AR
        • Suter T
        • Van der Meer P
        • Cardinale D
        • Lancellotti P
        • Zamorano JL
        • Bax JJ
        • Asteggiano R
        Council of Cardio-Oncology of the European Society of Cardiology. Anticoagulation in patients with atrial fibrillation and active cancer: an international survey on patient management.
        Eur J Prev Cardiol. 2021; 28: 611-621
        • D'Souza M
        • Carlson N
        • Fosbøl E
        • Lamberts M
        • Smedegaard L
        • Nielsen D
        • Torp-Pedersen C
        • Gislason G
        • Schou M.
        CHA2DS2-VASc score and risk of thromboembolism and bleeding in patients with atrial fibrillation and recent cancer.
        Eur J Prev Cardiol. 2018; 25: 651-658
        • Friberg L
        • Rosenqvist M
        • Lip GY.
        Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish atrial fibrillation cohort study.
        Eur Heart J. 2012; 33: 1500-1510
        • Toma M
        • Rrapaj E
        • Spallarossa P
        • Guerra F
        • Ameri P.
        Patterns of anticoagulation for atrial fibrillation in cancer patients referred to cardio-oncological evaluation.
        Eur J Intern Med. 2020; 82: 128-129
        • Al-Samkari H
        • Connors JM.
        Managing the competing risks of thrombosis, bleeding, and anticoagulation in patients with malignancy.
        Blood Adv. 2019; 3: 3770-3779
        • Hindricks G
        • Potpara T
        • Dagres N
        • Arbelo E
        • Bax JJ
        • Blomström-Lundqvist C
        • Boriani G
        • Castella M
        • Dan GA
        • Dilaveris PE
        • Fauchier L
        • Filippatos G
        • Kalman JM
        • La Meir M
        • Lane DA
        • Lebeau JP
        • Lettino M
        • Lip GYH
        • Pinto FJ
        • Thomas GN
        • Valgimigli M
        • Van Gelder IC
        • Van Putte BP
        • Watkins CL
        ESC Scientific Document Group. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS).
        Eur Heart J. 2021; 42: 373-498